MMQCI releases Xpert PML-RARA linearity, control materials
November 2024—Maine Molecular Quality Controls has launched reference materials for the Cepheid Xpert PML-RARA assay.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Randox now offers Olink panels
November 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.
Illumina unveils MiSeq i100 series benchtop sequencers
November 2024—Illumina has unveiled its MiSeq i100 series of sequencing systems, the MiSeq i100 and MiSeq i100 Plus.
Biofidelity launches Aspyre lung reagents
November 2024—Biofidelity announced the launch of its Aspyre Lung reagents for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer biomarkers in DNA and RNA from tissue and blood in a single, four-step workflow and runs on existing qPCR platforms.
Pillar launches OncoReveal Nexus NGS assay
November 2024—Pillar Biosciences has announced the global launch of OncoReveal Nexus, a research use only next-generation sequencing kit designed to assess key driver genes for hematological and solid tumor malignancies in one multiplex reaction.
Pillar, AstraZeneca partner to expand access to liquid biopsy testing
October 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next-generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants. The partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians, and patients through rapid and affordable kitted NGS testing solutions.
Thermo Fisher gets clearance for MGUS assay
October 2024—Thermo Fisher Scientific announced it received FDA 510(k) clearance to market its Optilite Freelite assays for the evaluation of monoclonal gammopathy of undetermined significance. The assays measure kappa and lambda free light chains in serum, enabling the identification of even small concentrations of monoclonal FLC proteins undetectable by serum protein electrophoresis.
AI enhancement added to PathoZoom LiveView
October 2024—Smart In Media announced an AI enhancement to its PathoZoom LiveView microscope camera and software. This system incorporates “AI on the fly,” which allows users to run AI routines from their own microscope. Users select a region of interest in the field of view and AI results are returned in a few seconds. PDL-1, Ki67, ER, and PR are available now on Smart In Media’s AI menu.
Bio-Rad launches Annexin V StarBright conjugates
October 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. The Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options, and enable full use of all common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright dyes, reduces spillover and spreading to provide high-resolution data.
MMQCI releases Spotfire RSP controls
October 2024—Maine Molecular Quality Controls now offers Spotfire RSP Controls for the Biofire Spotfire Respiratory/Sore Throat Panel Mini assay. The controls are intended for use as an external assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of pathogens on all Biofire Spotfire respiratory assays performed on the Spotfire system. The kit contains six positive and six negative controls in 300-µL tubes. Maine Molecular Quality Controls 207-885-1072